Evolving Landscape of Respiratory Viral Infections in Hematopoietic Cellular and CAR T-cell Therapy Recipients Post-COVID-19 Pandemic
hematopoietic cell transplantCAR T-cell therapyrespiratory viral infectionsimmunocompromised hostSARS-CoV-2
Highlight
- Respiratory viral infections (RVIs) remain a frequent complication within the first 100 days after hematopoietic cell transplantation (HCT) and CAR T-cell therapy, with an overall cumulative incidence of 7.4%.
- SARS-CoV-2 is now the most common respiratory virus identified in this vulnerable population, accounting for 43% of RVIs, followed by parainfluenza virus and RSV.
- CART-cell therapy recipients experience a higher incidence of RVI (12.7%) compared to allogeneic (7.8%) and autologous (4.7%) HCT recipients, with severe lower respiratory tract infections (LRTIs) occurring frequently in the setting of recent tocilizumab exposure and lymphopenia.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.